12/4
07:57 am
adct
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
Medium
Report
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
12/3
03:13 pm
adct
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
High
Report
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/3
11:03 am
adct
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
High
Report
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
12/3
07:53 am
adct
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
High
Report
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
12/3
07:30 am
adct
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
High
Report
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/2
04:26 pm
adct
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]
High
Report
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]
12/2
04:05 pm
adct
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
High
Report
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
12/1
04:05 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Medium
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
12/1
11:38 am
adct
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
11/12
08:05 am
adct
ADC Therapeutics (NYSE:ADCT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
ADC Therapeutics (NYSE:ADCT) had its "buy" rating reaffirmed by analysts at Guggenheim.
11/10
04:19 pm
adct
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... [Yahoo! Finance]
Medium
Report
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... [Yahoo! Finance]
11/10
11:24 am
adct
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
10:11 am
adct
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/10
07:59 am
adct
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update [Yahoo! Finance]
Low
Report
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update [Yahoo! Finance]
11/10
07:40 am
adct
ADC Therapeutics Non-GAAP EPS of -$0.19, revenue of $15.8M misses by $0.99M [Seeking Alpha]
Low
Report
ADC Therapeutics Non-GAAP EPS of -$0.19, revenue of $15.8M misses by $0.99M [Seeking Alpha]
11/10
07:30 am
adct
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
Medium
Report
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
11/3
07:15 am
adct
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
Medium
Report
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
10/27
07:15 am
adct
ADC Therapeutics to Present at November Investor Conferences
Medium
Report
ADC Therapeutics to Present at November Investor Conferences
10/26
06:31 am
adct
ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted [Yahoo! Finance]
Low
Report
ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted [Yahoo! Finance]
10/16
08:08 am
adct
ADC Therapeutics (NYSE:ADCT) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
ADC Therapeutics (NYSE:ADCT) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
10/13
07:39 am
adct
ADC Therapeutics Announces $60 Million Private Placement [Yahoo! Finance]
Medium
Report
ADC Therapeutics Announces $60 Million Private Placement [Yahoo! Finance]
10/13
07:30 am
adct
ADC Therapeutics Announces $60 Million Private Placement
Medium
Report
ADC Therapeutics Announces $60 Million Private Placement
10/3
02:37 pm
adct
ADC Therapeutics (NYSE:ADCT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ADC Therapeutics (NYSE:ADCT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
04:05 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Low
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
10/1
04:38 am
adct
Lymphoma Antibody Drug Conjugates Market Clinical Trials Insight 2030, by Company, Country, Indication and Phase [Yahoo! Finance]
Low
Report
Lymphoma Antibody Drug Conjugates Market Clinical Trials Insight 2030, by Company, Country, Indication and Phase [Yahoo! Finance]